Managing IP is part of the Delinian Group, Delinian Limited, 8 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
Cookies Settings

As good as new: why IP is central to repurposed drugs

Charlotte Kilpatrick
April 15, 2021
Share
drug-repurpose-min.jpeg

Sources from the pharmaceutical industry explain why research organisations should learn about IP before trying to bring an approved drug to market

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login

Tags

IP StrategyNewsInternationalPatents
kilpatrick-charlotte-300px.png
Charlotte Kilpatrick
Reporter Managing IP
Contact
Charlotte reports on patent-related issues. She often covers the European market, focusing on developments including FRAND, licensing and trade secrets. She is particularly interested in how new technologies affect IP challenges in the pharmaceutical industry.
more from across site and ros bottom lb

More from across our site

IP office.jpg
Weekly take: India’s IP office must keep users in the loop
The IPO must change its approach and communicate with IP owners about its attempts at clearing up the trademark register
Sukanya Sarkar, March 31, 2023
ForeignFilingsPatentCOVer.jpg
US IP counsel scrutinise foreign filings amid economic concerns
Counsel are looking at enforceability, business needs and cost savings when filing for patents overseas
Rani Mehta, March 31, 2023
David vs Goliaf
Key considerations for start-ups looking to license to bigger firms
James Perkins, member at Cole Schotz in Texas, reveals how smaller tech companies can protect themselves when dealing with larger players
James Perkins, March 31, 2023
commission.jpg
This week on MIP: Unitary SPCs; Delhi victory for Ericsson
We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
Rory O’Neill, March 31, 2023
Christian-Archambeau-EUIPO-Alicante.jpg
Exclusive: Council chasing EUIPO for Archambeau assessment
The EUIPO management board must provide the Council of the EU with a performance assessment before it can remove the executive director
Rory O’Neill, March 30, 2023
People communicate European Commission building.Brussels, Belgium - 02 Mar 2011
Unitary SPC will join SEPs in EU patent shake-up
The European Commission confirmed that plans for a unitary SPC will be published in April alongside reforms to the SEP system
Rory O’Neill, March 30, 2023
Ericsson.jpeg
Delhi High Court doubles Ericsson royalty in SEP appeal
The court held that SEP implementers could be injuncted or directed to pay royalties before trial if they are deemed to be unwilling licensees
Sukanya Sarkar, March 30, 2023
EPO
End of ‘painful’ EPO plausibility test a win for patentees
Patentees should feel cautious optimism over the EPO Enlarged Board of Appeal’s decision in G2/21, say European patent attorneys
Rory O’Neill, March 30, 2023
Berlin / Germany - September 22, 2019: Sanofi Germany - Berlin b
Counsel predict Sanofi victory in SCOTUS enablement case
Significant changes to the standard of law are unlikely, say sources, who note that some justices seemed sceptical that the parties disagreed on the legal standard
Rani Mehta, March 29, 2023
Australian HC.jpeg
Counsel: Australian TM edict could weaken big brands’ power
Sources say the High Court of Australia’s ruling that reputation is immaterial in trademark infringement cases could stop famous brands from muscling out smaller players
Sukanya Sarkar, March 29, 2023